Quipment
Quipment is recorded as a service provider in 103 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 103 trials · Latest update first
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Sponsor Johnson & Johnson Enterprise Innovation Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Sponsor Corvus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease
Sponsor Vor Biopharma Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).
Sponsor Alfasigma S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
Sponsor Exelixis Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Sponsor Mirati Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
Sponsor Dianthus Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
Sponsor Inmagene LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia
Sponsor Biomarin Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI) - ARTEMIA study
Sponsor OSE Immunotherapeutics
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
Sponsor Heidelberg Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)
Sponsor Bluefin Biomedicine Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Parallel-Group, Observer-Blind, Randomised, Placebo-Controlled, Pivotal Trial Investigating the Safety and Immunogenicity of Group B Streptococcus Vaccine (GBS-NN/NN2) in Pregnant Women and Infants Born to Pregnant Women Vaccinated During Pregnancy
Sponsor Minervax ApS
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosus
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)
Sponsor Bluefin Biomedicine Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.
Sponsor VectorY Therapeutics B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Quipment?
The 2026-10-09 snapshot links Quipment to 103 distinct CTIS trials. Recorded services include Equipment rental, Equipment Rental, Medicinal product management, Cardiac services, among 75 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Quipment?
The most frequently recorded therapeutic areas are Immunology, Dermatology, Solid Tumor Oncology, Genetic and Congenital Disorders. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Quipment conducted?
The linked trials record locations in 26 countries, including Spain, Germany, France, Poland, Italy. These are trial locations, not confirmed office locations or countries where Quipment delivered services.
What can this page tell me about Quipment's trial experience?
Browse 103 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 4 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Quipment. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Quipment
- Quipment Inc